Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library AV Room | Available |
c.1 BC Cancer Agency ARHCC Library | Available | ||
c.1 BC Cancer Agency KEL Library | Available | ||
c.1 BC Cancer Agency SUR Library | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available |
c.1 BC Cancer Agency KEL Library | Available |
Table of Contents:; Chapter 1: Clinical Trials: Historical Aspects and Importance and New Drug Developments -- Chapter 2: The Definition of GCP -- Chapter 3: The Principles of GCP -- Chapter 4: The Drug Development Process and Evolution of Regulations -- Chapter 5: Planning Clinical Research -- Cha…
c.1 BC Cancer Agency KEL Library | Available |
Contents:; The International System for Reporting Serous Fluid Cytopathology: Introduction and Overview of Diagnostic Terminology and Reporting -- Non-diagnostic (ND) and Adequacy -- Negative for Malignancy (NFM) -- Atypia of Undetermined Significance -- Suspicious for Malignancy (SFM) -- Malignant…